Close Menu
Home › ImaginAb Initiates Phase II Study of CD8 PET Tracer at Dana-Farber Cancer Institute

ImaginAb Initiates Phase II Study of CD8 PET Tracer at Dana-Farber Cancer Institute

Jul 24, 2019
|
staff reporter

NEW YORK – Immuno-oncology imaging firm ImaginAb has initiated a Phase II trial of its positron emission tomography (PET) imaging agent [89] Zr-Df-IAB22M2C at Dana-Farber Cancer Institute.

The imaging agent uses antibody fragments, so called "minibodies," engineered by ImaginAb to target CD8-positive T cells, and illuminate them with the help of PET imaging. The platform is being developed to provide a whole-body snapshot of immune activity, including that of cancer lesions, which in turn could be used to tailor treatment more precisely to patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
21
Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

What's Popular?

In Cancer

  1. Colon Cancer Recurrence Clues Identified in Post-Treatment ctDNA Detection

  2. Inivata Collecting Evidence for Liquid Biopsy in Immunotherapy Prediction, Response Monitoring

    Premium

  3. Exact Sciences, Mayo Clinic Launch Real-World Impact Study for Cologuard

  4. Gut Microbiome May Affect Cancer Patients' Responses to Immunotherapy, Emerging Research Shows

    Premium

  5. CHMP Issues Positive Decision for Keytruda in First Line PD-L1 Positive Head, Neck Cancer

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.